Our data provides new insights to the development of novel strategies to inhibit tumor angiogenesis in glioma by targeting Bmi-1, suggesting a necessity of further investigations of the anti-glioma therapeutic value of Bmi-1. This evidence concerns the gene BMI1 and central nervous system cancer.